Jeffrey Anderson, MD
Research Support: AstraZeneca
Consultant: Daiichi Sankyo/Lilly, Bristol-Myers Squibb, sanofi-aventis
Will discuss non-FDA-approved products or off-label usage of fondaparinux and bivalirudin.

Caroline Apovian, MD
Research Support: Gates, Pfizer, sanofi-aventis, Orexigen, Amylin
Consultant: Merck, Arena, sanofi-aventis

Louis Aronne, MD
Research Support: Amylin Pharmaceuticals, Arena Pharmaceuticals, Merck & Co., Novo Nordisk, Orexigen Therapeutics,  Pfizer, Schering-Plough, Trans Tech Pharma, Inc.
Scientific Advisor: Amylin Pharmaceuticals, Genaera Corp., GI Dynamics, GlaxoSmithKline, Johnson & Johnson,
Merck & Co., NeuroSearch, Novo Nordisk, Orexigen Therapeutics, Pfizer Inc., sanofi-aventis, Vivus, Inc.
Will discuss non-FDA-approved products or off-label usage of Tesofensine, Leptin, Lorcaserin, Qnexa, Contrave,
Empatic, and Victorza. 
Will discuss non-FDA-approved products or off-label usage for weight loss: topiramate, pramlintide, exenatide, and liraglutide.

Richard Bergman, PhD
Research Support: Amylin, sanofi-aventis
Consultant: Tethys Bioscience
Stock/Shareholder: Tethys Bioscience
Speaker’s Bureau: Merck
Has received $10,000 or more in the last 12 months from Merck, whose products or services may be mentioned in this activity.
Will discuss non-FDA-approved products or off-label usage of rimonabant (a CB-1 inhibitor), CVT-3619 (adenosine agonist), and guanethidine for sympathectomy.

Christopher Cannon, MD
Research Support: Accumetrics, AstraZeneca, Bristol-Myers Squibb/Sanofi Partnership, GlaxoSmithKline, Merck, Merck Schering-Plough Partnership
Clinical Advisor: Equity in Automedics Medical Systems
Will discuss non-FDA-approved products or off-label usage of prasugrel and ticagrelor for ACS.

Anthony Cincotta, PhD
A.H. Cincotta is the president and CSO of VeroScience and has a conflict of interest respecting presentation of Cycloset clinical data within the context of Continuing Medical Education symposia and the promotional marketing and commercialization of Cycloset.

Robert Cooper, MD
Nothing to disclose.

Ralph DeFronzo, MD
Grant Support: Bristol-Myers Squibb, Amylin, Eli Lilly, Novartis, Pfizer, Takeda, Roche, Merck
Speaker’s Bureau: Amylin, Eli Lilly, Takeda
Advisory Board: Bristol-Myers Squibb, Amylin, Eli Lilly, Novartis, Pfizer, Takeda, Roche, Johnson & Johnson

Michael Farkouh, MD
Research Support: Merck, Bristol-Myers Squibb, GlaxoSmithKline, VIA
Consultant: sanofi-aventis, Novartis

Kenneth Fujioka, MD
Research Support: Orexigen, EnteroMedics, Amylin, Roche, Nastech, Pfizer, Arena, Merck, Sanofi, Obecure
Consultant: Novo Nordisk, Amylin, Merck, Sanofi
Will discuss non-FDA-approved products or off-label usage of Contrave, Qnexa, and lorcaserin.

Om Ganda, MD
Speaker’s Bureau: Daiichi Sankyo

J. Michael Gaziano, MD
Financial Support: Investigator initiated research funding for the trial to be discussed.

Thomas Giles, MD
Research Support: Forest, Novartis
Consultant: Forest, Boehringer Ingelheim

Ronald Goldberg, MD
Research Support: Abbott, GlaxoSmithKline, Merck, Roche, Takeda
Consultant: Daiichi-Sankyo, GlaxoSmithKline, Takeda
Speaker: Abbott, Daiichi-Sankyo, GlaxoSmithKline, Merck, Takeda

Alan Gradman, MD
Consultant: NicOx

Joseph Izzo, MD
Research Support: Novartis, GlaxoSmithKline, Daiichi Sankyo
Consultant: Merck, Medical Education Consultants, Novartis, GlaxoSmithKline, SCS Healthcare, Daiichi Sankyo, Medplan
Speaker’s Bureau: Merck, Medical Education Consultants, Novartis, SCS Healthcare, Daiichi Sankyo, Medplan

David Kendall, MD
Research Support: Abbott Diabetes Care, Amylin Pharmaceuticals, Bayer Diabetes Care, DexCom, Eli Lilly & Co., MannKind, Merck, NIH-NHLBI, Novo Nordisk, Roche, sanofi-aventis
Consultant, Scientific & Clinical Advisory Board Activity, and Educational Funding: Amylin Pharmaceuticals, Bayer Diabetes Care, Daiichi Sankyo, Eli Lilly & Co., HealthPartners, Intarcia, Merck, Roche, Takeda, UnitedHealth Group
Employment: Wife is current employee of Roche.
All industry-sponsored research activity, advisory/consultancy work, and educational services are performed under contract to the nonprofit Park Nicollet Institute and the International Diabetes Center. Dr. Kendall receives no personal compensation for these activities.

Michael Landzberg, MD
Research Support: Actelion, Myogen, Gilead, NMT Medical
Other Financial Support: Implant medical devices as therapy in the cath lab.

Wendy Lane, MD
Research Support: Eli Lilly, Insulet Corp.
Consultant: Eli Lilly & Co.
Speaker’s Bureau: Eli Lilly & Co.
Has received $10,000 or more in the last 12 months from Eli Lilly & Co., whose products or services may be mentioned in this activity.
Will discuss non-FDA-approved products or off-label usage.

Harold Lebovitz, MD
Advisory Board: Amylin, ATCC, Biocon Pharma, Indigene, Intarca Pharmaceuticals, MetaCure, Poxel Pharma
Consultant: Amylin, AstraZeneca, Biocon Pharma, Enzymotec, GlaxoSmithKline (International), GI Dynamics, MetaCure, Novo Nordisk,
sanofi-aventis, VeraLight
Stock/Shareholder: Amylin, Merck
Speaker’s Bureau: GlaxoSmithKline (International), Lilly (International)
Has received $10,000 or more in the last 12 months from GlaxoSmithKline, Biocon Pharmaceuticals, Amylin Pharmaceuticals, and Intarcia, whose products or services may be mentioned in this activity.
Will discuss non-FDA-approved products or off-label usage of pramlintide-leptin (phase 3 studies) in reducing body weight and the published studies comparing the addition of pramlintide to prandial insulin in type 2 patients inadequately controlled on oral agents and basal insulin.  Will mention new long-acting incretin mimetics that have concluded phase 3 trials and are currently being reviewed by the FDA.

Preston Mason, PhD
Research Support: Forest Laboratories; Pfizer, Inc.
Consultant: NicOx
Speaker’s Bureau: Forest Laboratories
Has received $10,000 or more in the last 12 months from Forest Laboratories and Pfizer, Inc., whose products or services may be mentioned in
this activity.

Darren McGuire, MD, MHSc
Research Support: GlaxoSmithKline, Biosite, Inc.
Consultant: Tethys Bioscience, AstraZeneca, Novo Nordisk
Will discuss non-FDA-approved products or off-label usage of drugs demonstrated to improve glycometabolic parameters and/or prevent diabetes: alpha-glucosidase inhibitors, metformin, thiazolidinediones, ranolazine, ACE inhibitors, ARBs, and rimonabant.

Suzanne Oparil, MD
Research Support: Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Forest Laboratories, GlaxoSmithKline, Novartis, Merck & Co., Pfizer, Daiichi Sankyo
Consultant: Bristol-Myers Squibb, Daiichi Sankyo, Novartis, sanofi-aventis, The Salt Institute

Anne Peters, MD
Consultant: Amylin, Abbott Diabetes Care, Lilly, Medtronic Minimed, Novo Nordisk, Takeda
Speaker’s Bureau: Amylin, Abbott Diabetes Care, Lilly, Medtronic Minimed, Novo Nordisk, Takeda
Has received $10,000 or more in the last 12 months from Amylin, Abbott Diabetes Care, Lilly, Medtronic Minimed, Novo Nordisk, and Takeda, whose products or services may be mentioned in this activity.

Richard Pratley, MD
Research Support: Novartis, Takeda, Merck, Roche, Lilly, Novo Nordisk, MannKind, sanofi-aventis
Consultant: Novartis, Takeda, Merck, Roche, Novo Nordisk
Stock/Shareholder: Novartis
Speaker’s Bureau: Novartis, Takeda, Merck, Novo Nordisk
Other Financial Support: Honorarium: Novartis, Takeda, Merck, Roche, Novo Nordisk

Ioana Preston, MD
Research Support: Actelion, Gilead, United Therapeutics
Consultant: Actelion, Gilead, United Therapeutics, Bayer
Speaker’s Bureau: Actelion, Gilead
Will present data from recent clinical trials regarding the safety and efficacy of different treatments in patients with early (mild) pulmonary hypertension; some of these treatments are not currently approved by the FDA for this specific indication.

Marc Sabatine, MD
Research Support: (for Timi Study Group) Accumetrics, Amgen, AstraZeneca, Bayer Healthcare, Beckman Coulter, Biosite, Bristol-Myers Squibb, CV Therapeutics, Eli Lilly & Co., GlaxoSmithKline, Inotek Pharmaceuticals, Integrated Therapeutics, Merck & Co., Millennium Pharmaceuticals, Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, sanofi-aventis, Schering-Plough Research Institute
Research Support: diaDexus, Ortho Clinical Diagnostics, sanofi-aventis, Schering-Plough
Advisory Board: AstraZeneca, sanofi-aventis, Singulex
Speaker’s Bureau: Bristol-Myers Squibb, sanofi-aventis
Other Financial Support: Honorarium: Bristol-Myers Squibb, Eli Lilly, sanofi-aventis, Novartis
Has received $10,000 or more in the last 12 months from AstraZeneca, Bristol-Myers Squibb, diaDexus, Eli Lilly, Ortho Clinical Diagnostics,
sanofi-aventis, Schering-Plough, and Singulex, whose products or services may be mentioned in this activity.
Will discuss non-FDA-approved doses of clopidogrel and will discuss prasugrel.

Jeffrey  Sager, MD
Research Support: Actelion, Gilead
Consultant: Actelion, UT, Gilead, Lung Rx, Pfizer
Speaker’s Bureau: Actelion, UT, Gilead, Pfizer
Has received $10,000 or more in the last 12 months from Actelion, whose products or services may be mentioned in this activity.

Jay Skyler, MD
Research Support: Bayhill Therapeutics; Halozyme, Inc; Osiris Therapeutics, Inc.
Stock/Shareholder: Amylin Pharmaceuticals; DexCom Corporation; Ideal Life; MannKind Corporation; Medingo, Ltd.; Patton Medical Devices; Tandem Diabetes Care; Tethys Bioscience
Speaker’s Bureau: Novo Nordisk
Board of Directors Member: Amylin Pharmaceuticals; DexCom Corporation; Moerae Matrix, Inc.
Advisory Board: Patton Medical Devices; Valeritas, LLC
Advisor: BD Technologies; Ideal Life; Johnson & Johnson; MannKind Corporation; Medingo, Ltd.; Merck; Novo Nordisk; Salutria (Atherogenics); sanofi-aventis; Tethys Bioscience; Teva; Valeritas, LLC
Has received $10,000 or more in the last 12 months from Amylin Pharmaceuticals, DexCom Corporation, Novo Nordisk, and sanofi-aventis, whose products or services may be mentioned in this activity.
Will discuss non-FDA-approved products or off-label usage.

Raymond Townsend, MD
Research Support: NIH, Novartis, NicOx
Consultant: Roche, Spacelabs, GlaxoSmithKline, Protherics

William White, MD
Research Support: NIH; Novartis Consultant: NicOx, Inc.; Savient; Takeda
Speaker’s Bureau: Forest
Has received $10,000 or more in the last 12 months from NicOx, Inc. whose products or services may be mentioned in this activity.
Will discuss non-FDA approved products or off-label usage of naproxicinod.

Carol Wysham, MD
Consultant: Amylin Pharmaceuticals
Speaker’s Bureau: Amylin, Eli Lilly & Co, Merck, Novo Nordisk, sanofi-aventis
Has received $10,000 or more in the last 12 months from Amylin and Eli Lilly & Co., whose products or services may be mentioned in this activity.

Bernard Zinman, MD
Research Support: GlaxoSmithKline, Novo Nordisk, Merck
Consultant: GlaxoSmithKline, Amylin, Eli Lilly, Merck, Novartis